MAOB and glioblastoma: Overall, the results suggest that the novel MAO-B inhibitors Cmp3 and Cmp5 significantly upregulate oxidative stress in glioblastoma cells, leading to cell cycle arrest and reduced cell migration, which may enhance their therapeutic potential against this aggressive cancer [111].